Clive Page’s main research interests are in the pharmacology of inflammation and respiratory disease
() has appointed Clive Page, professor of pharmacology at King's College London, to its medical advisory board.
In a statement, the NEX-listed CBD wellness and medicinal cannabis company noted that Page’s main research interests are in the pharmacology of inflammation and respiratory disease, having published over 300 scientific papers and book chapters, and he is a fellow of the Royal Society of Biology and an honorary fellow of the British Pharmacological Society.
Nick Horniman, director of regulatory affairs at Sativa commented: “Professor Page is an eminent research scientist and will add to Sativa's experience, interest and understanding in cannabis-based medical products."
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE